Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer

Olsen, Dorte Aalund; Jakobsen, Erik; Brandslund, Ivan

doi:10.1515/cclm-2013-0166

Cited by 8 publications

(9 citation statements)

References 17 publications

(20 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the current study, we found no correlation between the presence of autoantibodies and patient survival. Similar findings have been reported in ovarian and breast cancer [ 36 , 37 ] and may indicate that autoantibodies to zinc finger proteins are more suitable for diagnostic or screening purposes rather than disease prognosis.…”

Section: Discussionsupporting

confidence: 85%

Diagnostic Potential of Zinc Finger Protein-Specific Autoantibodies and Associated Linear B-Cell Epitopes in Colorectal Cancer

O’Reilly

Fitzgerald

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

Colorectal cancer is one of the most common cancers worldwide with almost 700,000 deaths every year. Detection of colorectal cancer at an early stage significantly improves patient survival. Cancer-specific autoantibodies found in sera of cancer patients can be used for pre-symptomatic detection of the disease. In this study we assess the zinc finger proteins ZNF346, ZNF638, ZNF700 and ZNF768 as capture antigens for the detection of autoantibodies in colorectal cancer. Sera from 96 patients with colorectal cancer and 35 control patients with no evidence of cancer on colonoscopy were analysed for the presence of ZNF-specific autoantibodies using an indirect ELISA. Autoantibodies to individual ZNF proteins were detected in 10–20% of colorectal cancer patients and in 0–5.7% of controls. A panel of all four ZNF proteins resulted in an assay specificity of 91.4% and sensitivity of 41.7% for the detection of cancer patients in a cohort of non-cancer controls and colorectal cancer patients. Clinicopathological and survival analysis revealed that ZNF autoantibodies were independent of disease stage and did not correlate with disease outcome. Since ZNF autoantibodies were shared between patients and corresponding ZNF proteins showed similarities in their zinc finger motifs, we performed an in silico epitope sequence analysis. Zinc finger proteins ZNF700 and ZNF768 showed the highest sequence similarity with a bl2seq score of 262 (E-value 1E-81) and their classical C2H2 ZNF motifs were identified as potential epitopes contributing to their elevated immunogenic potential. Our findings show an enhanced and specific immunogenicity to zinc finger proteins, thereby providing a multiplexed autoantibody assay for minimally invasive detection of colorectal cancer.

show abstract

Section: Discussionsupporting

confidence: 85%

Diagnostic Potential of Zinc Finger Protein-Specific Autoantibodies and Associated Linear B-Cell Epitopes in Colorectal Cancer

O’Reilly

Fitzgerald

et al. 2015

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…FISH was used to detect the gene amplification status when HER-2 immunohistochemistry was + or ++. The results of EGFR, MMP-2, E-cadherin and N-cadherin were evaluated in line with the publication from Queiroga et al, Olsen et al, van Duijnhoven et al and Elzagheid et al [12][13][14][15].…”

Section: Methodssupporting

confidence: 55%

The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes

Min¹,

Wang²,

Guo³

et al. 2020

World J Oncol

View full text Add to dashboard Cite

show abstract

“…After excluding 579 non‐English articles and 1318 duplicates, 4441 articles not relevant to the topic and 58 meeting the exclusion criteria were excluded. Ultimately, 84 articles were included . A total of 196 specific tumour‐associated autoantibodies (Table S1) were reported, of which 23 specific tumour‐associated autoantibodies (Table ) had been studied more than once.…”

Section: Resultsmentioning

confidence: 99%

“…The most commonly used detection method was ELISA (60 studies) (Table S1). Western blot [21,26,60,76,80,81,83,[87][88][89] or immunoprecipitation [74,87] was often used to confirm positive results. Twelve studies used only Western blot [30,33,36,45,46,51,57,62,75,85,92,97], and six studies used O-glycopeptide or autoantigen microarray [10,37,38,41,50,67] to detect the tumourassociated autoantibody.…”

Section: Tumour-associated Autoantibody Detection Methodsmentioning

confidence: 99%

Tumour‐Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta‐Analysis

et al. 2016

View full text Add to dashboard Cite

Tumour-associated autoantibodies may be promising biomarkers that could facilitate breast cancer (BC) diagnosis and improve patient outcomes. This review aims to identify the tumour-associated autoantibodies with the greatest diagnostic potential. Systematic searches were conducted using PubMed and Web of Science. The most studied tumour-associated autoantibody was included in a meta-analysis, and its clinical value was determined using Fagan's nomogram. The analysis included 84 studies regarding tumour-associated autoantibodies with the diagnostic value. Anti-p53 antibody was the most frequently studied autoantibody, followed by autoantibodies against MUC1, HER2 and cyclin B1. Although individual tumour-associated autoantibodies showed low diagnostic sensitivity, combinations of autoantibodies offered relatively high sensitivity. Enzyme-linked immunosorbent assay (ELISA) was the most common detection method, and nucleic acid programmable protein microarrays appeared preferable to common protein microarrays. As the most commonly studied autoantibody, anti-p53 antibody was included in a metaanalysis. When it had been detected using ELISA and cut-off values were defined as the mean +2 or 3 standard deviations, the summary area under the receiver operating characteristic curve for the presence of BC was 0.78. Fagan's nomogram showed post-test probabilities of 32% and 6% for positive and negative results, respectively. Mammography might be supplemented by the use of tumour-associated autoantibodies as biomarkers for BC diagnosis in younger women with increased risks of BC. Even though several studies have investigated the diagnostic use of tumour-associated autoantibodies as biomarkers for BC detection, a high-quality prospective study is needed to validate their diagnostic value in practice.

show abstract

Quantification of EGFR autoantibodies in the amplification phenomenon of HER2 in breast cancer

Abstract: S-EGFRAb can be measured accurately using the ELISA we developed. We conclude that autoantibodies against EGFR do not seem to be associated with the HER2 gene amplification phenomenon.

Cited by 8 publications

References 17 publications

Diagnostic Potential of Zinc Finger Protein-Specific Autoantibodies and Associated Linear B-Cell Epitopes in Colorectal Cancer

Diagnostic Potential of Zinc Finger Protein-Specific Autoantibodies and Associated Linear B-Cell Epitopes in Colorectal Cancer

The Effect of Metformin on the Clinicopathological Features of Breast Cancer With Type 2 Diabetes

Tumour‐Associated Autoantibodies as Diagnostic Biomarkers for Breast Cancer: A Systematic Review and Meta‐Analysis

Contact Info

Product

Resources

About